These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10722507)

  • 1. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
    Fletcher CV; Brundage RC; Remmel RP; Page LM; Weller D; Calles NR; Simon C; Kline MW
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1029-34. PubMed ID: 10722507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
    Kline MW; Fletcher CV; Federici ME; Harris AT; Evans KD; Rutkiewicz VL; Shearer WT; Dunkle LM
    Pediatrics; 1996 Jun; 97(6 Pt 1):886-90. PubMed ID: 8657531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
    Gatti G; Vigano' A; Sala N; Vella S; Bassetti M; Bassetti D; Principi N
    Antimicrob Agents Chemother; 2000 Mar; 44(3):752-5. PubMed ID: 10681350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
    Mole L; Schmidgall D; Holodniy M
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
    Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
    Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
    Villalba N; Gómez-Cano M; Casas E; Soriano V; Valencia E; González-Lahoz J
    AIDS; 1997 Dec; 11(15):1896-7. PubMed ID: 9412717
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
    Kakuda TN; Page LM; Anderson PL; Henry K; Schacker TW; Rhame FS; Acosta EP; Brundage RC; Fletcher CV
    Antimicrob Agents Chemother; 2001 Jan; 45(1):236-42. PubMed ID: 11120972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
    Regazzi MB; Villani P; Maserati R; Seminari E; Pan A; LoCaputo F; Gambarana E; Fiocchi C
    J Antimicrob Chemother; 2000 Mar; 45(3):343-7. PubMed ID: 10702554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
    Becher F; Landman R; Mboup S; Kane CN; Canestri A; Liegeois F; Vray M; Prevot MH; Leleu G; Benech H
    AIDS; 2004 Jan; 18(2):181-7. PubMed ID: 15075534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
    de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
    HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ddI + d4T + IDV well tolerated in HIV-infected children.
    AIDS Patient Care STDS; 1997 Oct; 11(5):373. PubMed ID: 11361822
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.